CD8A and melanoma: Findings showed that the ΔTK‐Armed‐VACV induced tumor‐specific CD8+ T cells, the release of IFN‐γ, and repressed tumor growth in A549 or 4T1 tumor‐bearing mice models.[153] Oncolytic adenovirus AdV‐D24‐ICOSL‐CD40L expressing potent costimulatory molecules could be effective in the clinic via inducing antitumor immune responses in melanoma therapy.